382150.KQ
Oncocross Co., Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 3,450.00
−2.68%Year over year
Reported trailing growth
- Revenue
- -61.9%
- EBITDA
- -94.2%
- EBIT
- -22.3%
- EPS
- +18.0%
- Free cash flow
- -26.0%
- Operating cash flow
- -10.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +35.1%
- EBITDA
- -32.4%
- EBIT
- -26.8%
- Net income
- -37.7%
- EPS
- -20.6%
- Free cash flow
- -87.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026